Approval · Notice of Compliance 6005 · 2004
OVIDREL: Notice of Compliance 6005
Issued December 16, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6005
- Date
- December 16, 2004
- Company
- Serono Canada Inc.
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Gonadotropin
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OVIDREL | 02262061 | — |
| OVIDREL | 02262088 | Marketed |
Medicinal ingredients
- CHORIOGONADOTROPIN ALFA 250 MCG per VIAL
- CHORIOGONADOTROPIN ALFA 250 MCG per 0.5ML